Viridian Therapeutics IncDE
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
ITEM 6. EXHIBIT INDEX
The exhibits listed in the Exhibit Index are required by Item 601 of Regulation S-K. The SEC file number for all items incorporated by reference herein from reports on Forms 10-K, 10-Q, and 8-K is 001-36483.
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit No. · Description of Exhibit · Form · Filing Date · Number | |||||
| 3.1 | Second Restated Certificate of Incorporation of the Registrant, effective as of March 9, 2022. | 10-K | 3/11/2022 | 3.1 | |
| 3.2 | Fourth Amended and Restated Bylaws of the Registrant, effective as of December 15, 2023. | 8-K | 12/18/2023 | 3.1 | |
| 3.3 | Certificate of Designation of Series A Non-Voting Convertible Preferred Stock. | 8-K | 10/28/2020 | 3.1 | |
| 3.4 | Certificate of Designation of Series B Non-Voting Convertible Preferred Stock. | 8-K | 9/23/2021 | 3.1 | |
| 4.1 | Specimen Common Stock Certificate. | S-1 | 3/19/2014 | 4.1 | |
| 10.1 | Separation Agreement and Consulting Agreement, dated as of March 1, 2025, by and between the Registrant and Thomas Ciulla. | x | |||
| 10.2 | Open Market Sale Agreement, dated March 3, 2025 by and between Viridian Therapeutics, Inc. and Jefferies LLC. | 8-K | 3/4/2025 | 1.1 | |
| 10.3 | Radhika Tripuraneni Employment Agreement, dated February 23, 2025. | x | |||
| 31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended. | x | |||
| 31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended. | x | |||
| 32.1* | Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | x | |||
| 101.INS | XBRL Instance Document | x | |||
| 101.SCH | XBRL Taxonomy Extension Schema Document | x | |||
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | x | |||
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | x | |||
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document | x | |||
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | x | |||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | x | |||
| + | Indicates management contract or compensatory plan |
|---|---|
| * | This certification is being furnished pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Exchange Act and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof. |
| x | Filed/furnished herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| VIRIDIAN THERAPEUTICS, INC. | ||
| Date: May 6, 2025 | By: | /s/ Stephen Mahoney |
|---|---|---|
| Stephen Mahoney | ||
| President, Chief Executive Officer and Director | ||
| (Principal Executive Officer) | ||
| Date: May 6, 2025 | By: | /s/ Seth Harmon |
| Seth Harmon | ||
| Chief Financial Officer | ||
| (Principal Financial Officer; Principal Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.